Harmony Biosciences Holdings, Inc.
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $868.5M
- Net income
- $158.7M
- Total assets
- $1.3B
- Market cap
- $1.9B
- Gross margin
- 77.2%
- Operating margin
- 24.0%
- Net margin
- 18.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $868.5M
- Cost of revenue
- $198.3M
- Gross profit
- $670.1M
- Operating expenses
- $461.6M
- Operating income
- $208.5M
- Income tax
- $56.4M
- Net income
- $158.7M
- EPS (basic)
- $2.76
- EPS (diluted)
- $2.71
Balance sheet
- Total assets
- $1.3B
- Current assets
- $907.0M
- Total liabilities
- $401.4M
- Current liabilities
- $252.1M
- Shareholders’ equity
- $870.2M
Cash flow
- Operating cash flow
- $348.2M
- Investing cash flow
- -$39.6M
- Financing cash flow
- -$9.0M
- Net cash flow
- $299.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.9B
- P/E ratio
- 12.0
- EPS (diluted)
- $2.71
- Shares outstanding
- 57.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 19, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $158.7M in FY2025.
- Revenue grew 184% from FY2021 to FY2025.
- Gross margin of 77.2%, net margin 18.3%.
- Trading 20% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 12.0.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Harmony Biosciences Holdings, Inc..
Write a review
News about Harmony Biosciences Holdings, Inc.
News & sentiment via Polygon.io
